Melanoma
Managing Immunotherapy-Related GI Complications
Immunotherapy has been lauded as a game changer for cancer patients, but these therapies can result in toxicities.
JUNE 30, 2025
Remote Telemedicine Tool Highly Accurate in Diagnosing Melanoma
Sending images of suspicious-looking skin growths to off-site for specialists to analyze is as accurate in identifying melanomas as having a dermatologist examine them in person.
APRIL 18, 2025
Survivorship Planning for Melanoma Patients
3 Questions for Christina Davis, PharmD, Clinical Oncology Pharmacy Specialist, University of Colorado Anschutz Medical Campus, about managing survivors of melanoma.
APRIL 4, 2025
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo, Bristol Myers Squibb) indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy, Bristol Myers Squibb) combination therapy, or in combination with chemotherapy or cabozantinib.
DECEMBER 30, 2024
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.
NOVEMBER 27, 2024
Immunotherapy Before Surgery for Stage III Melanoma Significantly Improves Outcomes
After resection of stage III melanoma, adjuvant immunotherapy has previously been associated with a reduction in the risk for recurrence, which has proven to be common even with tumor-free margins, but a new phase 3 study shows that immunotherapy before surgery reduces this risk.
JUNE 24, 2024
Amtagvi Granted Accelerated Approval for Unresectable or Metastatic Melanoma
The FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
FEBRUARY 16, 2024
FDA Approves Opdivo for Adjuvant Treatment of Select Patients With Stage IIB/C Melanoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.
OCTOBER 17, 2023
Are TILs Ready to Rescue Melanoma Treatment Failures?
Tumor-infiltrating lymphocytes (TILs) may extend survival in patients with treatment-resistant melanoma, experts noted during the HOPA Annual Conference 2023, in Phoenix.
OCTOBER 2, 2023
FDA Approves Hepzato Kit as a Liver-Directed Treatment for Uveal Melanoma
The FDA approved Hepzato Kit (melphalan for Injection/Hepatic Delivery System) containing melphalan (Hepzato, Delcath Systems Inc.) as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues or lung that is amenable to resection or radiation.
AUGUST 17, 2023
In Phase 3 Trial, Tumor-Infiltrating Cells Found Highly Effective in Advanced Melanoma
A phase 3 trial comparing tumor-infiltrating cells (TILs) and a checkpoint inhibitor for the treatment of advanced melanoma favored TILs for every end point. The results included a greater than twofold increase in the proportion of patients achieving a complete response.
NOVEMBER 4, 2022
Nivolumab Plus Relatlimab Approved to Treat Metastatic Melanoma
The FDA approved a fixed-dose combination of the programmed death-1–blocking antibody nivolumab and relatlimab-rmbw, a lymphocyte activation gene-3–blocking antibody, to treat patients aged 12 years and older with unresectable or metastatic melanoma.
MARCH 22, 2022
